Aggrenox End-Payors Want $18M Atty Fees In $54M Deal
Indirect buyers of Aggrenox told a Connecticut federal judge Friday that attorneys who represented the putative class alleging that Teva Pharmaceutical and Boehringer Ingelheim blocked generic alternatives to the stroke-prevention drug...To view the full article, register now.
Already a subscriber? Click here to view full article